Technology ID
TAB-2854
Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir
E-Numbers
E-195-2013-0
Lead Inventor
Heneine, Walid (CDC)
Co-Inventors
Folks, Thomas (CDC)
Janssen, Robert (CDC)
Otten, Ronald (CDC)
Garcia Lerma, Jose (CDC)
Applications
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vivo data available (animal)
- In vivo data available (human)
Lead IC
CDC
ICs
CDC
The invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TDF, significantly increases the level of protection against HIV transmission.
Commercial Applications
- Oral, prophylactic delivery of combination drugs to inhibit HIV infection
Licensing Contact: